The medical community is buzzing with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 agonist that’s demonstrating significant promise in clinical trials for addressing obesity. Unlike some current weight loss approaches, retatrutide appears to provide a significant substantial d